On July 14, 2026, the Federal Trade Commission secured a settlement with Caremark Rx LLC and Zinc Health Services LLC that will require the pharmacy benefit manager to make substantive changes to its business practices. The agreement marks another significant step in the federal government's ongoing scrutiny of the pharmacy benefit management industry and establishes benchmarks that participants across the drug pricing ecosystem should carefully evaluate. For pharmacy benefit managers (PBMs), health plans, and community pharmacies, the settlement offers meaningful insight into the compliance expectations that federal regulators are prepared to enforce.
The settlement is structured around three core objectives. First, it targets a reduction in patients' out-of-pocket costs, an area that has drawn sustained attention from lawmakers, regulators, and consumer advocates concerned about the affordability of prescription medications. Second, it requires enhanced transparency in PBM operations, addressing longstanding concerns about the opacity of formulary decisions, rebate arrangements, and pricing methodologies. Third, it obligates the company to ensure fair treatment of community pharmacies, which have raised persistent concerns about reimbursement practices, network access, and contract terms that they contend disadvantage independent providers relative to affiliated dispensers.
While the settlement directly binds only Caremark and Zinc Health Services, its practical significance extends much further. By articulating federally-endorsed expectations for PBM conduct, the settlement effectively provides a roadmap that other industry participants should measure their own practices against. Companies engaged in PBM operations, or those contracting with PBMs, may wish to review their contracting frameworks, pricing structures, rebate flows, and pharmacy network arrangements to identify areas of potential regulatory exposure. Health plans should consider whether their PBM agreements align with the transparency and cost-containment principles reflected in the settlement, and community pharmacies may find useful leverage in the standards articulated by the FTC when negotiating or challenging network terms.
The settlement also signals that federal enforcement in this space is unlikely to abate. Organizations should anticipate continued regulatory attention and prepare for the possibility that these standards will inform future enforcement actions, rulemaking initiatives, and state-level policy developments.
This article is provided for general informational purposes only and does not constitute legal advice. Clients with questions regarding how this settlement may affect their operations or contractual arrangements should seek tailored guidance from qualified counsel.